FATE

Fate Therapeutics Inc

May 15 • 04:00PM ET

1.75

-0.14 -7.63 %

Healthcare • Biotechnology • USA • Micro • NASD

| Held by: IWM VTI IWN VXF SCHA VTWO IWC PRFZ VHT DFAS

Index	RUT	P/E	-	EPS (ttm)	-1.09	Insider Own	4.72%	Shs Outstand	116.27M	Perf Week	-26.57%
Market Cap	204.56M	Forward P/E	-	EPS next Y	-1.03	Insider Trans	-0.29%	Shs Float	111.05M	Perf Month	28.10%
Enterprise Value	106.52M	PEG	-	EPS next Q	-0.28	Inst Own	69.14%	Short Float	9.23%	Perf Quarter	40.40%
Income	-129.91M	P/S	32.37	EPS this Y	3.72%	Inst Trans	-0.03%	Short Ratio	4.97	Perf Half Y	68.75%
Sales	6.32M	P/B	1.14	EPS next Y	7.25%	ROA	-38.01%	Short Interest	10.26M	Perf YTD	78.61%
Book/sh	1.55	P/C	1.17	EPS next 5Y	3.07%	ROE	-55.50%	52W High	2.46 -28.80%	Perf Year	73.76%
Cash/sh	1.50	P/FCF	-	EPS past 3/5Y	26.67% 11.42%	ROIC	-51.60%	52W Low	0.91 92.86%	Perf 3Y	-67.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-58.98% -26.71%	Gross Margin	-97.69%	Volatility	14.35% 10.91%	Perf 5Y	-97.71%
Dividend TTM	-	EV/Sales	16.85	EPS Y/Y TTM	26.97%	Oper. Margin	-2207.47%	ATR (14)	0.21	Perf 10Y	10.38%
Dividend Ex-Date	-	Quick Ratio	5.85	Sales Y/Y TTM	-52.64%	Profit Margin	-2056.79%	RSI (14)	50.75	Recom	1.91
Dividend Gr. 3/5Y	- -	Current Ratio	5.85	EPS Q/Q	18.19%	SMA20	0.63%	Beta	2.25	Target Price	5.17
Payout	-	Debt/Eq	0.43	Sales Q/Q	-20.26%	SMA50	22.99%	Rel Volume	1.00	Prev Close	1.90
Employees	161	LT Debt/Eq	0.40	Earnings	May 13 BMO	SMA200	42.83%	Avg Volume	2.06M	Price	1.75
IPO	Oct 01, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.14% -12.93%	Trades		Volume	2,059,249	Change	-7.63%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-27-25	Upgrade	Wedbush	Neutral → Outperform	$7
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90
Jul-28-22	Initiated	Needham	Hold

Show Previous Ratings

May-13-26 08:35AM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press) -5.11%
08:30AM	Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
May-11-26 08:30AM	Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting (GlobeNewswire) -8.79%
May-05-26 08:30AM	Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 (GlobeNewswire) +31.11%
May-04-26 09:00AM	Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases (GlobeNewswire) +17.65%
04:05PM	Loading…
May-01-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +22.40%
Apr-30-26 09:00AM	Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR - East 2026 Meeting (GlobeNewswire)
Apr-16-26 09:00AM	Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting (GlobeNewswire) +6.20%
Apr-09-26 09:00AM	Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences (GlobeNewswire) +7.63%
Apr-02-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire)
Mar-04-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.84%
Mar-03-26 04:05PM	Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire) -8.67%
10:02AM	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (PR Newswire)
Feb-26-26 01:30PM	Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.41%
09:15AM	Loading…
09:15AM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
09:00AM	Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-03-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.69%
Jan-26-26 10:16AM	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets (PR Newswire)
Jan-05-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-08-25 08:00AM	Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs (GlobeNewswire)
Nov-25-25 08:00AM	Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 09:40AM	Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56% -8.40%
10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
08:15AM	Incyte (INCY) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-26-25 11:30AM	Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy (GlobeNewswire)
Oct-14-25 08:00AM	Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer (GlobeNewswire) +7.91%
04:01PM	Loading…
Oct-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 08:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.22%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire) -5.31%
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +20.69%
04:30PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-11-25 06:55PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates (Zacks) -5.76% -5.99%
Aug-06-25 07:45AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-05-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 04:57PM	Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data (Insider Monkey)
07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-03-25 01:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 11:30AM	Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? (Zacks) -9.68%
Jun-11-25 09:00AM	Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress (GlobeNewswire) -7.19%
Jun-10-25 10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks) +9.87%
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire) -8.33% +7.44%
May-28-25 11:46PM	Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases (Insider Monkey)
05:54PM	Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress (GlobeNewswire)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.54%
04:01PM	Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65% -10.69%
Apr-29-25 09:25AM	Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting (GlobeNewswire) -6.40%
Apr-15-25 10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks) +21.17%
Apr-14-25 08:00AM	Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) (GlobeNewswire) -12.80%
Apr-04-25 11:30AM	Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? (Zacks) +10.72%
Apr-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.69%
Mar-05-25 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +14.90%
04:12PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.77%
Feb-17-25 10:00AM	Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-25 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +11.81% +7.75%
Feb-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.40%
Jan-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-24 11:30AM	Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? (Zacks) -11.70%
Dec-09-24 04:01PM	Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus (GlobeNewswire) -16.18%
Dec-03-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.15%
Dec-02-24 09:55AM	Fate Therapeutics makes Bob Valamehr president and CEO (Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM	Fate Therapeutics Announces Leadership Transition (GlobeNewswire)
Nov-26-24 04:01PM	Fate Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire) +10.74% +18.28%
Nov-18-24 08:05AM	Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence (GlobeNewswire) +12.38%
08:00AM	Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence (GlobeNewswire)
Nov-12-24 05:20PM	Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.03% -8.82%
04:18PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-09-24 01:30PM	Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting (GlobeNewswire)
Nov-08-24 04:01PM	Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting (GlobeNewswire) -5.10% +5.79%
Nov-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.58%
Oct-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 04:01PM	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire) +7.49%
11:30AM	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? (Zacks)
Aug-16-24 12:00PM	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:25PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.12% -9.50%
Jul-31-24 08:00AM	Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors (GlobeNewswire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:01PM	Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 10:48AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 02:50PM	Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ... (GuruFocus.com)
10:36AM	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating (MT Newswires)
08:22AM	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating (MT Newswires)
May-09-24 08:58PM	FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.41%
05:25PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Ph.D.Dr. Bahram Valamehr M.B.A.

MBAMr. Kamal Adawi M.S.

Chief Legal & Compliance Officer and Corporate SecretaryMs. Cindy R. Tahl J.D.

Senior Vice President of Human Resources & OperationsMs. Jessica Francis

Head of ResearchDr. Martin Hosking

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TAHL CINDY	See Remarks	May 06 '26	Option Exercise	1.25	166,664	207,997	653,745	May 07 04:00 PM
EPSTEIN ROBERT S	Director	May 05 '26	Option Exercise	1.69	25,000	42,250	36,331	May 06 04:01 PM
RASTETTER WILLIAM H	Director	May 05 '26	Option Exercise	1.69	25,000	42,250	36,331	May 06 04:00 PM
TAHL CINDY	See Remarks	Jan 09 '26	Sale	1.06	10,589	11,275	387,081	Jan 12 04:04 PM
Valamehr Bahram	President and CEO	Jan 09 '26	Sale	1.07	5,190	5,557	329,708	Jan 12 04:03 PM
TAHL CINDY	Officer	Jan 09 '26	Proposed Sale	1.06	10,589	11,275		Jan 09 03:08 PM
Valamehr Bahram	Officer	Jan 09 '26	Proposed Sale	1.07	5,190	5,557		Jan 09 03:08 PM
MENDLEIN JOHN	Former Director	Dec 24 '25	Proposed Sale	1.01	38,428	38,881		Dec 29 02:44 PM
TAHL CINDY	See Remarks	Aug 04 '25	Sale	1.06	9,037	9,573	397,670	Aug 05 04:03 PM
Valamehr Bahram	President and CEO	Aug 04 '25	Sale	1.06	14,466	15,396	334,898	Aug 05 04:02 PM
TAHL CINDY	Officer	Aug 04 '25	Proposed Sale	1.06	9,037	9,573		Aug 04 04:56 PM
Valamehr Bahram	Officer	Aug 04 '25	Proposed Sale	1.06	14,466	15,396		Aug 04 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FATE

Fate Therapeutics Inc

Upgrade your Finviz experience